Parkinson’s Real World Impact assesSMent
A descriptive, exploratory observational study with cross-sectional design.
Parkinson’s Real World Impact assesSMent (PRISM) study is a descriptive, exploratory observational study with cross-sectional design. A pan-European survey was designed by an International Scientific Committee in collaboration with The Cure Parkinson’s Trust (a United Kingdom-based research-driven charity), aiming to evaluate the burden of Parkinson’s disease (PD), medication use, healthcare resource utilisation (HCRU) and health-related quality of life (HRQoL) of people with Parkinson’s (PwP) and their care partners.
Prof. Eduardo Tolosa (Spain); Prof. Georg Ebersbach (Germany); Prof. Joaquim J. Ferreira (Portugal), Prof. Olivier Rascol (France), Prof. Angelo Antonini (Italy), Prof. Thomas Foltynie (UK), and Prof. Andrew Lees (UK) as Chair
It contains data from 861 PwP and 256 care-partners, gathered from 5 European countries: Germany, Italy, Portugal, Spain and UK. Data collected includes demographics, time since diagnosis, treatment patterns, characteristics of care-partner, HCRU and the following scales: PDQ-39 (HR QoL and Motor domain); NMSQuest; Medical Outcomes Study Sexual Functioning Scale; Zarit Burden Inventory.
Any health care professional or academic researcher is able to download the database after reading and understanding the PRISM Data Use Agreement and PRISM Publication Policy.
BIAL is an innovative pharmaceutical company, dedicated to discovering, developing and commercializing medicines, mainly focusing in CNS and Cardiovascular therapeutic areas. The mission of the company is to improve people’s lives worldwide; Keeping life in mind.
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.